BLACKSTONE LIFE SCIENCES
Blackstone Life Sciences (BXLS) fills a critical void in the industry. While life sciences is seeing unprecedented innovation driven by rapid advancements in science and technology, it often lacks the necessary funding to bring medicines and healthcare technologies to market. We work in partnership with the pharmaceutical, biotechnology and medical technology industries to help meet this need.
BLACKSTONE LIFE SCIENCES
Status:
Active
Similar Organizations
BBH Capital Partners
The private-equity arm of New York
Oaktree Capital Management
Oaktree Capital Management is a privately owned investment manager specializing in alternative investment strategies.
Perceptive Advisors
Perceptive Advisors is a privately owned hedge fund sponsor that finances the public equity markets across the globe.
Platform Ventures
Platform Ventures, a real estate private equity investment firm.
Rhone Capital
Rhone Capital is a private equity arm of Rhone Group.
Current Advisors List
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-03-15 | Sanofi | Blackstone Life Sciences investment in Post-IPO Equity - Sanofi | 300 M EUR |
| 2021-08-10 | Harmony Biosciences | Blackstone Life Sciences investment in Post-IPO Equity - Harmony Biosciences | 30 M USD |
| 2020-11-19 | Imago BioSciences | Blackstone Life Sciences investment in Series C - Imago BioSciences | 80 M USD |
| 2020-10-06 | Talaris Therapeutics | Blackstone Life Sciences investment in Series B - Talaris Therapeutics | 115 M USD |
| 2020-07-28 | Praxis Precision Medicines | Blackstone Life Sciences investment in Series C - Praxis Precision Medicines | 110 M USD |
| 2020-07-01 | Annexon Biosciences | Blackstone Life Sciences investment in Series C - Annexon Biosciences | 100 M USD |
| 2020-06-15 | Medtronic | Blackstone Life Sciences investment in Post-IPO Equity - Medtronic | 337 M USD |
| 2020-06-11 | Reata Pharmaceuticals | Blackstone Life Sciences investment in Post-IPO Equity - Reata Pharmaceuticals | 350 M USD |
| 2020-04-13 | Alnylam Pharmaceuticals | Blackstone Life Sciences investment in Post-IPO Equity - Alnylam Pharmaceuticals | 250 M USD |
More informations about "Blackstone Life Sciences"
Life Sciences - Blackstone
Jun 30, 2025 Blackstone Life Sciences helps bring important medicines and technologies to market to improve patient outcomes.See details»
Blackstone Life Sciences - Crunchbase Company Profile & Funding
Blackstone Life Sciences (BXLS) operates in the biotechnology sector, focusing on investments in advanced healthcare technologies to improve patient outcomes. The firm invests in both early …See details»
Nicholas Galakatos - Global Head of Blackstone Life …
Feb 12, 2025 Global Head of Blackstone Life Sciences (BXLS) · BXLS combines investing and operational expertise, committing our domain skill and …See details»
Our People - Blackstone
Our employees are integral to the firm’s culture of integrity, professionalism and excellence.See details»
How blackstone life sciences is bridging the innovation gap
Blackstone Life Sciences' Paris Panayiotopoulos discusses the role of funding and strategic partnerships in advancing biopharma innovation. Listen now.See details»
Blackstone Life Sciences - Financial Details - Crunchbase
Blackstone Life Sciences is a private equity segment of The Blackstone Group.See details»
Blackstone Life Sciences Expands Team of Biopharmaceutical, …
May 24, 2021 Cambridge, MA – Blackstone Life Sciences, the life sciences business of Blackstone (NYSE:BX), today announced the appointments of Dr. Olivier Brandicourt, former …See details»
Blackstone Launches New $5B+ Fund for Life Sciences
Jan 31, 2025 Blackstone joins other big investors such as ARCH Venture Partners and Bain Capital Life Sciences in pumping billions of dollars into the industry. Alternative investment management firm Blackstone on Thursday …See details»
Blackstone Life Sciences Launches Uniquity Bio to …
May 15, 2024 With Blackstone Life Sciences supporting the company’s capital requirements, Uniquity Bio has a unique and sustainable business model that supports the parallel development of high-potential medicines along with a …See details»
Blackstone Announces $4.6 Billion Final Close of Life …
Jul 9, 2020 Blackstone Life Sciences is a private, global investment platform with capabilities to invest across the life-cycle of companies and products within the key life science sectors. By combining scale investments and hands-on …See details»
Blackstone Life Sciences - Profiles & Contacts - Crunchbase
Blackstone Life Sciences has 5 current employee profiles, including Founder Stephen Schwarzman.Blackstone Life Sciences has 4 board members and advisors, including Robert …See details»
Blackstone Life Sciences - News & Analysis - Crunchbase
Jun 26, 2025 Blackstone Life Sciences is a private equity segment of The Blackstone Group.See details»
Blackstone Life Sciences - Growth Outlook - Crunchbase
Blackstone Life Sciences is a private equity segment of The Blackstone Group.See details»
Home - Blackstone
Blackstone is the world’s largest alternative asset manager, serving institutional and individual investors by building strong businesses positioned to deliver lasting value.See details»
How Blackstone Life Sciences is bridging the innovation gap
Jul 24, 2025 Life science companies today face growing financial pressure in advancing new therapies—challenged by rising R&D costs and constrained budgets. Blackstone Life Sciences …See details»
Blackstone Life Sciences V: Fund Performance | PitchBook
Jan 19, 2024 General Information Description Blackstone Life Sciences V is a 2020 vintage private equity growth and expansion fund co-managed by Blackstone Life Sciences and …See details»
Blackstone targets $5 billion for latest life sciences fund
Dec 9, 2024 Blackstone is back on the fundraising trail for its latest life sciences fund, targeting $5 billion in investor commitments, the Wall Street Journal reported, citing pension documents.See details»
Blackstone-backed biotech launches with up to $300M for …
May 15, 2024 Blackstone has made a wide range of life sciences investments in recent years, including a promise of as much as $750 million for Moderna to support the research and …See details»
How Blackstone Life Sciences is bridging the innovation gap
Jul 24, 2025 Paris Panayiotopoulos, Senior Managing Director at Blackstone Life Sciences, shares how the firm’s broad life sciences strategy has been advancing innovation across the …See details»
How Blackstone Bolted Past Rivals in Life Sciences
May 13, 2024 Blackstone’s business model is well suited for life sciences. Its $1 trillion of assets under management are spread over more than 230 portfolio companies and massive holdings …See details»